Thermo Fisher Scientific (NYSE:TMO) Rating Lowered to Hold at DZ Bank

Thermo Fisher Scientific (NYSE:TMO) was downgraded by stock analysts at DZ Bank from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, Zacks reports.

Several other equities research analysts have also issued reports on the stock. Barclays increased their target price on shares of Thermo Fisher Scientific from $750.00 to $775.00 and gave the stock an “overweight” rating in a research note on Thursday. Morgan Stanley raised their target price on Thermo Fisher Scientific from $650.00 to $730.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Scotiabank initiated coverage on Thermo Fisher Scientific in a research note on Wednesday, September 9th. They issued an “outperform” rating for the company. Royal Bank Of Canada upped their price target on Thermo Fisher Scientific from $580.00 to $730.00 and gave the stock a “sector perform” rating in a report on Thursday. Finally, Citigroup increased their price target on Thermo Fisher Scientific from $685.00 to $800.00 and gave the stock a “buy” rating in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $681.00.

Thermo Fisher Scientific Stock Performance

TMO opened at $673.97 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.81 and a quick ratio of 1.18. The firm has a fifty day moving average price of $645.72 and a 200 day moving average price of $554.80. Thermo Fisher Scientific has a 1 year low of $435.27 and a 1 year high of $705.78. The stock has a market cap of $249.20 billion, a P/E ratio of 35.55, a P/E/G ratio of 2.81 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $0.28. The firm had revenue of $12.14 billion for the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.79 earnings per share. Equities research analysts anticipate that Thermo Fisher Scientific will post 25.20 earnings per share for the current year.

Insider Activity at Thermo Fisher Scientific

In related news, VP Lisa P. Britt sold 11,440 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the transaction, the vice president owned 14,784 shares in the company, valued at $9,064,366.08. This represents a 43.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Joseph R. Holmes sold 420 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 73,768 shares of company stock valued at $44,122,820 in the last three months. Company insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of hedge funds have recently made changes to their positions in the company. Legacy Wealth Managment LLC ID increased its position in shares of Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after purchasing an additional 22 shares in the last quarter. Kilter Group LLC acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at $25,000. Allied Private Wealth LLC purchased a new position in Thermo Fisher Scientific in the 2nd quarter valued at $26,000. Pingora Partners LLC purchased a new position in Thermo Fisher Scientific in the 2nd quarter valued at $30,000. Finally, Navigoe LLC acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth $31,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations. Thermo Fisher reported adjusted earnings of $6.68 per share versus the $6.40 consensus, while revenue rose 9.1% year over year to $12.14 billion, topping estimates of $11.95 billion. TMO Q3 deep dive: pharma demand, AI integration, and end-market recovery drive momentum
• Positive Sentiment: Analysts raised their valuation targets. TD Cowen increased its target to $810 and maintained a buy rating, while Stifel raised its target to $775 and Baird lifted its target to $756 with an outperform rating. These revisions imply meaningful upside from recent trading levels. TD Cowen analyst ratings
• Positive Sentiment: Improving end markets support the growth outlook. Investor commentary highlighted a broad-based recovery across life-science markets, including pharmaceutical demand, AI-related applications and other research tools. Erste Group also modestly raised its FY2027 EPS estimate to $27.58 from $27.51. Thermo Fisher benefits on broad-based recovery
• Neutral Sentiment: Secular market growth provides a longer-term tailwind. Industry forecasts call for strong expansion in next-generation sequencing kits and peptide synthesis, markets in which Thermo Fisher participates, although these reports do not directly change near-term earnings. NGS kits market forecast
• Negative Sentiment: Options activity signals caution. Heavy put-option buying indicates that some traders are hedging against, or positioning for, a pullback. The muted reaction to the earnings beat may also reflect elevated expectations and a relatively rich valuation. Thermo Fisher stock sees heavy put option buying

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.